Compare FLNC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNC | IOVA |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2021 | 2008 |
| Metric | FLNC | IOVA |
|---|---|---|
| Price | $19.77 | $4.25 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 10 |
| Target Price | ★ $15.71 | $9.00 |
| AVG Volume (30 Days) | 12.6M | ★ 12.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,262,830,000.00 | N/A |
| Revenue This Year | $51.23 | $47.74 |
| Revenue Next Year | $21.30 | $40.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $1.67 |
| 52 Week High | $33.51 | $5.63 |
| Indicator | FLNC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 56.07 |
| Support Level | $18.90 | $2.07 |
| Resistance Level | $23.90 | $4.35 |
| Average True Range (ATR) | 3.14 | 0.37 |
| MACD | -0.64 | 0.02 |
| Stochastic Oscillator | 3.51 | 51.00 |
Fluence Energy Inc provides intelligent energy storage and optimization software for renewables and storage. Its energy storage solutions and operational services support a more resilient grid and help unlock the potential of renewable portfolios. The company's offerings include energy storage solutions, recurring operational and maintenance services, and Software-as-a-Service (SaaS) products designed to meet customer business needs, performance requirements, in-house capabilities, and risk profiles. Its service plans offer varying levels of training, maintenance, guarantees, warranties, and support for active system management. The company operates in the Americas, APAC and EMEA, with the majority of revenue coming from the Americas.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.